enGene Therapeutics Inc. ENGN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 266.32M | 258.47M | 275.95M | 193.74M | 201.91M |
| Total Receivables | 2.88M | 2.92M | 3.70M | 2.23M | 709.00K |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 8.63M | 8.54M | 9.50M | 5.35M | 8.62M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 79.00K | 75.00K | 74.00K | 79.00K | 72.00K |
| Total Current Assets | 277.90M | 270.00M | 289.22M | 201.39M | 211.31M |
|
|
|||||
| Total Current Assets | 277.90M | 270.00M | 289.22M | 201.39M | 211.31M |
| Net Property, Plant & Equipment | 9.03M | 9.44M | 9.91M | 10.19M | 9.85M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 1.39M | 1.38M | 1.39M | 1.36M | 1.38M |
| Total Assets | 288.32M | 307.52M | 337.11M | 221.47M | 245.55M |
|
|
|||||
| Total Accounts Payable | 2.54M | 1.79M | 2.44M | 6.69M | 2.38M |
| Total Accrued Expenses | 21.56M | 16.26M | 19.44M | 14.68M | 9.94M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 2.45M | 2.48M | 2.51M | 10.02M | 6.94M |
| Total Finance Division Other Current Liabilities | 665.00K | 953.00K | 228.00K | 596.00K | 1.18M |
| Total Other Current Liabilities | 665.00K | 953.00K | 228.00K | 596.00K | 1.18M |
| Total Current Liabilities | 27.21M | 21.49M | 24.61M | 31.98M | 20.44M |
|
|
|||||
| Total Current Liabilities | 27.21M | 21.49M | 24.61M | 31.98M | 20.44M |
| Long-Term Debt | 25.16M | 24.91M | 24.74M | 15.32M | 17.71M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 5.67M | 5.96M | 6.22M | 6.46M | 6.73M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 58.03M | 52.36M | 55.57M | 53.76M | 44.88M |
|
|
|||||
| Common Stock & APIC | 696.15M | 688.32M | 684.17M | 540.63M | 536.03M |
| Retained Earnings | -464.51M | -432.01M | -401.78M | -372.03M | -334.15M |
| Treasury Stock & Other | -1.35M | -1.14M | -842.00K | -888.00K | -1.21M |
| Total Common Equity | 230.29M | 255.17M | 281.55M | 167.71M | 200.67M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 230.29M | 255.17M | 281.55M | 167.71M | 200.67M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 230.29M | 255.17M | 281.55M | 167.71M | 200.67M |
|
|
|||||